5 Investor presentation First six months of 2021 Sales growth of 12% driven by bo therapy areas Reported geographic sales split for the first half of 2021 DKK billion Insulin GLP-1 Growth at CER Other diabetes Obesity 42 13% 35 28 International Operations 21 11% 14 12% 16% 7 0 IO EMEA China RoW Biopharm 11% NAO 1 ‘Other diabetes’ is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of W Note: Unless otherwise specified, sales growth rates are at CER
Download PDF file